| Next 10 |
Ad
ALIM News and Press Alimera Sciences Inc.
News | Alimera Sciences Inc. (NASDAQ:ALIM)
-
Be Semiconductor Industries NV New York Shares (BESIY) is expected to report for Q3 2024 Carrier Global Corporation (CARR) is expected to report $0.81 for Q3 2024 Ameris Bancorp (ABCB) is expected to report $1.26 for Q3 2024 CBRE Group Inc Class A (CBRE) is expected to report $1.06 fo...
-
2024-09-16 09:04:44 ET More on Alimera Sciences Alimera Sciences: Deal Closing After All, CVR Still Attractive Alimera Sciences: Cheap CVR Optionality Alimera Sciences falls after it sues ANI Pharmaceuticals to close deal (update) Biggest stock movers today: ...
-
Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic...
-
2024-09-14 15:44:00 ET It was a busy week for mergers and acquisitions in the tech and finance industry, and commodities with big names such as Qualcomm ( QCOM ), UniCredit ( OTCPK:UNCFF ), Squarespace ( SQSP ), US Steel ( X ) grabbing headlines.... Read the ...
-
2024-09-14 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2024-09-11 11:16:14 ET More on ANI Pharma ceuticals ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028 ANI Pharmaceut...
-
2024-09-11 11:12:04 ET Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committe...
-
2024-09-11 07:23:09 ET More on ANI Pharmaceuticals ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028 ANI Pharmaceuticals ...
-
PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their t...
-
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (N...
Stock Information
Get ALIM Alerts
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
-0.18% G/L:
$5.54 Last:
2,679,904 Volume:
$5.55 Open:
$5.54 Close:
Alimera Sciences Inc. Website:
Ad
-
Be Semiconductor Industries NV New York Shares (BESIY) is expected to report for Q3 2024 Carrier Global Corporation (CARR) is expected to report $0.81 for Q3 2024 Ameris Bancorp (ABCB) is expected to report $1.26 for Q3 2024 CBRE Group Inc Class A (CBRE) is expected to report $1.06 fo...
-
Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic...
-
2024-09-14 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...